Article

Analysis of the Coding Transcriptome in NSCLC Highlights Variant-Specific Gene Expression and Signaling in CD74-ROS1 Fusions

2025-11-07

Abstract excerpt

The CD74-ROS1 fusion protein is an aggressive oncogenic driver detected in non-small cell lung cancer (NSCLC) patients from stages I-IV. Despite the low occurrence, CD74-ROS1 has a notable clinical value serving as a therapeutic target when the primary treatment plan fails. Upon targeting the cancer cells with ROS1 tyrosine kinase inhibitors (TKIs), resistance occasionally emerges for reasons that are not well-und...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dade5383-1fc2-534a-a041-8c194e98da3f
DOI: 10.20944/preprints202511.0530.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Analysis of the Coding Transcriptome in NSCLC Highlights Variant-Specific Gene Expression and Signaling in CD74-ROS1 FusionsDOI 10.20944/preprints202511.0530.v1Read

Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencingSemantic proximity Read

CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.Semantic proximity Read

Analysis of CD74 Occurrence in Oncogenic Fusion ProteinsSemantic proximity Read

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to CrizotinibSemantic proximity Read

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion ProteinsSemantic proximity Read

Survival of Patients with Advanced Non-Small Cell Lung Cancer Harboring Different ROS1 Fusion Subtypes: A Real-World StudySemantic proximity Read

Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter studySemantic proximity Read

“Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”Semantic proximity Read

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitorsSemantic proximity Read

Evaluation of ROS1 expression and rearrangements in a large cohort of early- stage lung cancerSemantic proximity Read

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.Semantic proximity Read